CB Scientific (CB Scientific) NonCurrent Deferred Liabilities : $0.15 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is CB Scientific NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

CB Scientific's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0.15 Mil.

CB Scientific NonCurrent Deferred Liabilities Historical Data

The historical data trend for CB Scientific's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CB Scientific NonCurrent Deferred Liabilities Chart

CB Scientific Annual Data

Trend

Mar21

Mar22

Mar23

NonCurrent Deferred Liabilities

CB Scientific Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial							-	-	0.15	0.15	0.15

CB Scientific NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of CB Scientific's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CB Scientific (CB Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CB Scientific Inc (OTCPK:CBSC) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135

Website

https://www.cbscientificinc.com

CB Scientific Inc through its U.S. and international subsidiaries provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.